Participated · Series B · Nov 2025

Founded in 2020, Osaka-based GramEye builds AI-driven robotic devices that automate the Gram-staining process used in infectious-disease diagnostics. Its flagship product, launched in January 2025 and already deployed in clinical laboratories, speeds and standardizes bacterial classification to guide timely antibiotic therapy. Leveraging user feedback, the company continues to enhance both the hardware and its image-recognition AI. GramEye’s roadmap includes pursuing FDA clearance for U.S. entry and creating a next-generation Clinical Decision Support System (CDSS) that delivers evidence-based antibiotic recommendations. By improving diagnostic speed and accuracy, the team aims to reduce inappropriate antibiotic use and mitigate the global AMR crisis. Financially, the company has secured 570 million yen in new Series B equity and, together with multiple public grants (including 4.2 billion yen from the NEDO PCA program), reports cumulative funding of 1.65 billion yen. The fresh capital will also support aggressive hiring across executive, engineering, and sales roles to scale globally.

Participated · Series B · May 2024

YADOKARI operates a "movable-asset" (可動産) platform business offering end-to-end services: planning and producing trailer/tiny‑house units, sales, operator support, PR/media and financing. The company has in‑house manufacturing in Aichi and is scaling production capacity (body+chassis ~100 units/year; chassis ~400 units/year) while recruiting nationwide partners. It pursues both B2B use cases (commercial, tourism/leisure) and a future entry into B2C residential markets, alongside region‑focused projects and PoCs for area development. YADOKARI runs services such as LIFESTOCK (shared ownership/operations) and DOSAN (movable-asset tourism) and operates media and facility projects that support community building. The firm emphasizes cultural and social initiatives, engaging external advisors to co‑create a distinctive cultural sphere and expand impact. Financially, it has raised cumulative funding of approximately ¥470M and is using new capital to strengthen manufacturing, sales/service, hiring and organizational capabilities.

Participated · Series A · Apr 2024

VARYTEX builds a suite of products centered on its "Kampo diagnostic support software," a SaMD-targeted program and related non-medical tools designed to help physicians use Kampo medicine appropriately and safely. The company is developing both clinician-facing decision support and research tools in collaboration with the Japanese Society of Oriental Medicine to collect clinical data and validate Kampo efficacy. Its products aim to assist non-specialist physicians, support Kampo specialists' workflows, and enable rapid AI-driven analysis of accumulated clinical data. VARYTEX has been iterating its product with university hospitals and obstetrics clinics and plans ongoing UI/UX and product-performance improvements. It also plans to formally launch the non-medical device "KAMPO365works" at the end of May as a precursor to medical-device approval. The company reports cumulative fundraising of ¥210M and completed a pre-Series A fundraising round to accelerate regulatory, clinical, and product efforts.

Participated · Series A · Mar 2024

Shinsekai Technologies develops and operates the community service suite “MURA,” originally designed for influencers’ fan communities and now expanding to enterprise use. MURA lets users join branded communities directly inside LINE, eliminating separate app downloads and boosting participation and retention. The platform doubles as a customer-data foundation, surfacing behavioral insights to improve CX, raise LTV and connect community activity to broader marketing and business objectives. Having refined its know-how in B2C settings, the company is rolling the product out to corporations and IP holders as an operating system for marketing DX and community-driven commerce. Future product work will emphasize AI-powered analytics, richer UX and integrations that turn communities into long-term corporate assets. Management also plans to extend MURA into social commerce, digital content and real-world experiences to build new economic ecosystems around fan “cliques.” The company has not yet disclosed specific revenue or user figures, noting that metrics will be released in stages.

Participated · Series A · Mar 2024

PECOFREE operates a student-focused food-delivery and school-lunch reservation platform that matches schools and local catering companies and offers a smartphone bento ordering service. The company was founded in February 2021 and is headquartered in Fukuoka City. Since its service launch in April 2021, PECOFREE has been adopted by over 500 facilities including schools, after-school care and companies, and school facility adoption accelerated 2.5x in the current term. The startup positions itself to drive DX in the industrial catering sector while building a monetizable system that combines social impact and commercial viability. PECOFREE says the newly raised funds will be used for system development, app UX improvements and new features, marketing/PR, and new hires. Its stated mission is to connect people through food and become a school food infrastructure that supports children across Japan.